Underreporting, Underrepresentation of Race, Ethnicity in Head, Neck Cancer Trials

JAMA Otolaryngology–Head & Neck Surgery

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JUNE 2, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/10.1001/jamaoto.2022.1028?guestAccessKey=21e05e03-bca1-414b-8ad6-31e2841bb6cb&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060222

 

About The Study: Researchers found in this systematic review of 155 head and neck cancer clinical trials from 2010 to 2020 that only 57% of the studies reported race or ethnicity. A comparison of these trials with the Surveillance, Epidemiology and End Results (SEER) cancer registries indicated that Black and Asian or Pacific Islander patients were underrepresented.

Authors: Linda X. Yin, M.D., of the Mayo Clinic in Rochester, Minnesota, is the corresponding author.

 

(doi:10.1001/jamaoto.2022.1028)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.